The present disclosure relates to the treatment of tuberculosis and/or multi-drug resistant tuberculosis by inhalable pharmaceutical compositions that include an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole. The present disclosure also relates to an inhalable pharmaceutical composition that includes an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole.